Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizurnab (BV): results from the BRITE registry

被引：0
|
作者：
Sing, A. [1 ]
Sugrue, M. [1 ]
Chiruvolu, R. [1 ]
Yi, J. [1 ]
Purdie, D. [1 ]
Dong, W. [1 ]
Grothey, A. [2 ]
Kozloff, M. [3 ]
机构：
[1] Genentech Inc, San Francisco, CA USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Chicago, Ingalls Hosp, Harvey, KS USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70973-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3045
引用
收藏
页码：249 / 249
页数：1
相关论文
共 50 条
  • [41] Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).
    Cremolini, Chiara
    Loupakis, Fotios
    Yang, Dongyun
    Salvatore, Lisa
    Zhang, Wu
    Wakatsuki, Takeru
    Schirripa, Marta
    Lonardi, Sara
    Antoniotti, Carlotta
    Aprile, Giuseppe
    Masi, Gianluca
    Graziano, Francesco
    Ruzzo, Annamaria
    Lucchesi, Sara
    Ronzoni, Monica
    Maus, Martin Karl Herbert
    Bocci, Guido
    Tonini, Giuseppe
    Falcone, Alfredo
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ± bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Baron, A. D.
    O'Bryant, C. L.
    Choi, Y.
    Ashkenazi, A.
    Royer-Joo, S.
    Portera, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Serious bleeding events are uncommon in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen. results from the brite observational cohort study
    Kozloff, M.
    Sugrue, M.
    Chiruvolu, P.
    Feng, S.
    Purdie, D.
    Grothey, A.
    Sargent, D.
    Berlin, J.
    Kabbinavar, F.
    Dong, W.
    Flynn, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [44] Right (R) or left (L) primary site of colorectal cancer and outcomes for metastatic colorectal cancer (mCRC): Results from the south Australian registry of mCRC.
    Price, Timothy Jay
    Beeke, Carol
    Padbury, Robert
    Maddern, Guy
    Roder, David
    Moore, James
    Rose, Amanda
    Roy, Townsend Amitesh
    Hocking, Christopher
    Karapetis, Christos Stelios
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [45] Do we know what to do with our nonagenarian and centenarian patients with metastatic colorectal cancer (mCRC)? Results from the South Australian mCRC registry
    Rico, Gonzalo Tapia
    Karapetis, Christos
    Townsend, Amanda R.
    Piantadosi, Cynthia
    Padbury, Rob
    Roy, Amitesh
    Maddern, Guy
    Moore, James
    Carruthers, Scott
    Roder, David
    Price, Timothy J.
    ACTA ONCOLOGICA, 2018, 57 (11) : 1455 - 1457
  • [46] Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (BEV) and sorafenib.
    Lafky, J. M.
    Bot, B. M.
    Morlan, B. W.
    Anderson, S. K.
    Kimlinger, T. K.
    Halling, T. M.
    Kumar, S.
    Reynolds, J. T.
    Stella, P. J.
    Dakhil, S. R.
    Loui, W. S.
    Alberts, S. R.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Utilization and cost of CPT-11 (C) in elderly previously treated metastatic colorectal cancer (MCRC) patients (pts).
    Eng, C
    Zhao, L
    Shih, YCT
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 266S - 266S
  • [48] Outcomes of long responders chemorefractory metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib: a single institution experience
    Sforza, V.
    Capasso, A.
    Nappi, A.
    Cardone, C.
    Martini, G.
    Ferrara, M. L.
    Napolitano, S.
    Vitiello, P.
    Vitale, P.
    Zanaletti, N.
    De Vita, F.
    Orditura, M.
    Troiani, T.
    Ciardiello, F.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Nonagenarian patients with metastatic colorectal cancer: Results from the South Australian metastatic colorectal cancer registry.
    Price, Timothy Jay
    Karapetis, Christos Stelios
    Piantadosi, Cynthia
    Padbury, Robert
    Roy, Amitesh Chandra
    Maddern, Guy
    Gonzalo, Tapia Rico
    Moore, James
    Roder, David
    Townsend, Amanda Rose
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [50] Predicting overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with chemotherapy (CT): The British Columbia Cancer Agency (BCCA) mCRC score
    Chen, Leo
    Gresham, Gillian
    Cheung, Winson Y.
    Kennecke, Hagen F.
    Renouf, Daniel John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345